Fig. 3From: Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapyOS for all patients who received dovitinib plus fulvestrant or placebo plus fulvestrant. NE Not estimable, OS Overall survivalBack to article page